A significant proportion of individuals suffer from persistent symptoms after acute infection with SARS-CoV-2. This syndrome, called long COVID by patient advocates, has been named post-acute sequelae of COVID-19 (PASC) by the National Institutes of Health. The World Health Organization developed a clinical case definition that includes (1) history of probable or confirmed SARS-CoV-2 infection with onset at least 3 months earlier and (2) symptoms that last for at least 2 months that cannot be explained by an alternative diagnosis.1

Basic, translational, clinical, and public health researchers have just started to understand the epidemiology and pathobiology of PASC,2 which continues to evolve along with changes in the pandemic, vaccines, and treatments. At the same time, post-COVID clinics have been developed around the world to provide care for individuals suffering from PASC. It is readily apparent that there are different clinical presentations of PASC (eg, neurologic, cardiopulmonary), but these remain poorly defined entities.3 Therefore, more research is needed to establish clinical phenotypes, to understand underlying mechanisms, and to identify potential therapeutic targets for the millions of individuals who are suffering or at risk for development of PASC.

In this issue of Mayo Clinic Proceedings, Ganesh et al4 describe the first 108 patients in the Mayo Clinic’s post—COVID-19 care clinic (PCOCC) who were evaluated at a median 149 days after acute infection. They report demographic characteristics, symptoms, laboratory findings, and 6-minute walk test results of adults referred for symptoms attributed to PASC. A notable strength of the study is inclusion of a large proportion of individuals who were not hospitalized during acute infection (84%).

Women made up the majority of those seeking care at the PCOCC, which is similar to other studies that have reported a female predominance of PASC,5-7 especially those that included nonhospitalized individuals. Among the study sample, they found notable differences in predominant phenotypes by sex; fatigue-, orthostasis-, and chest pain—predominant phenotypes were more common among women and dyspnea among men. Based on expert consensus, the authors grouped fatigue-, myalgia-, and orthostasis-predominant phenotypes as central sensitization (CS) phenotypes and compared them with the dyspnea/chest pain phenotype (cardiopulmonary phenotype). There was a higher proportion of women with CS phenotypes. These findings are consistent with reports that female sex is associated with specific PASC subtypes (fatigue/muscle weakness, anxiety/depression, diffusion impairment).8

Why are more women presenting for care for PASC? Possible explanations include differences in risk factors for SARS-CoV-2 infection or PASC; differences in severity, organ involvement, or immune response of acute illness; differences in PASC phenotypes (more women with multisystem symptoms and no evident organ dysfunction); differences in the trajectory of post-COVID inflammation or symptoms; and differences in care-seeking behavior. Men have a higher risk of mortality in acute COVID-19 accounting for comorbidities,9,10 possibly because of sex-related differences in the innate immune system. The gene encoding toll-like receptor 7 (TLR7), which activates the initial interferon response to SARS-CoV-2, is on the X chromosome and escapes X chromosome inactivation, resulting in higher expression in women.11 Loss-of-function mutations in TLR7 resulting in down-regulated interferon signaling have been found in young
men with severe COVID-19. Similarly, TLR7 expression and downstream interferon signaling may explain greater control of acute HIV infection but higher risk of progression to AIDS among women compared with men.

Female predominance is well established in autoimmunity and other postinfectious conditions that may be related to CS, such as myalgic encephalomyelitis/chronic fatigue syndrome, fibromyalgia, and postural orthostatic tachycardia syndrome. Central sensitization may be closely related to autonomic dysfunction. SARS-CoV-2 can infect the central nervous system, including the regions of the brain responsible for autonomic regulation. Microvascular thrombosis, autoimmunity, chronic immune activation and systemic inflammation, or localized inflammation of the peripheral autonomic nervous system (ie, in the heart) may also be implicated in PASC-associated autonomic dysfunction. Whether PASC is a distinct entity or whether COVID-19 is a risk factor for development of these other CS-associated syndromes is not yet known.

The second major finding was that the inflammatory cytokine interleukin 6 (IL-6) is elevated among most of those with PASC, with higher levels in women and those with the CS phenotype compared with the cardiopulmonary phenotype. It is interesting that the degree of IL-6 elevation varied by phenotype, especially in considering cardiopulmonary phenotype as the reference. Given the risk of confounding in this observational study, these analyses would have been strengthened by adjusting for likely confounders for the relationship between IL-6 and PASC including age, sex, time since acute infection, body mass index, and pertinent comorbidities as well as by inclusion of a control group. In a study of individuals with PASC in San Francisco, our group found that high-sensitivity C-reactive protein and possibly IL-6 were elevated in those with the cardiopulmonary phenotype. In our cohort, IL-6 level was 44% higher among those with PASC compared with those without PASC, with no change after adjustment for age, sex, hospitalization status, history of autoimmune disease, and body mass index. Others have found similar elevations in inflammatory markers, including IL-6, among those with PASC. In comparison with other non-PASC CS conditions, IL-6 is elevated in women with postural orthostatic tachycardia syndrome and individuals with fibromyalgia but not myalgic encephalomyelitis/chronic fatigue syndrome.

The consistent association of systemic inflammation and specifically elevated IL-6 with PASC across multiple studies raises the possibility of IL-6 inhibition as a potential PASC treatment. In acute COVID-19, IL-6 inhibition reduced all-cause mortality at 28 days on the basis of meta-analysis of 10 randomized controlled trials that collectively randomized 6428 patients. Yet IL-6 inhibition has not yet been studied as a potential intervention for PASC. Given the high burden of morbidity and uncertain long-term risks of PASC, studies of therapeutic strategies including IL-6 inhibition are urgently needed. Because of the risk of selection bias, the findings that clinical phenotypes vary by sex will require confirmation with rigorous epidemiologic population-based sampling. As a clinic-based study, individuals thought to have PASC, either self-referred or physician referred, were included in the study of Ganesh et al. Whether a positive SARS-CoV-2 test result was required is not described; if confirmatory testing was not required, individuals not infected with SARS-CoV-2 may bias the findings. The referral process excluded those with symptoms attributed to a single organ system, and importantly, those with already identified end-organ damage (such as pulmonary fibrosis) were also excluded. The authors did not report severity of acute infection by sex. Men who survived COVID-19 acute respiratory distress syndrome may have been more likely to be referred to PCOCC, hence more men with a dyspnea-predominant phenotype, whereas women with milder acute COVID-19 may be referred with CS phenotypes. Collectively these issues could lead to selection bias, which could be differential by sex. As noted by the authors, lack of racial and ethnic diversity is a limitation of the study. The COVID-19 pandemic has disproportionately affected non-White populations within the United States, and whether phenotypes of PASC vary
by race/ethnicity is not clear. Presumably many if not all of these patients were evaluated before vaccination, but this is not reported, and effects of vaccination on the natural history of PASC are not yet known. Nonetheless, the study provides valuable insights into the phenotypes of PASC seen in clinical practice at post-COVID clinics and strengthens the evidence that IL-6 is elevated among those with PASC.

Matthew S. Durstenfeld, MD
Priscilla Y. Hsue, MD
Department of Medicine
University of California, San Francisco
Division of Cardiology
Zuckerberg San Francisco General Hospital
San Francisco, CA

Michael J. Peluso, MD, MPH, MHS, DTM&H
Steven G. Deeks, MD
Division of HIV, Infectious Diseases and Global Medicine
Zuckerberg San Francisco General Hospital
University of California, San Francisco

Grant Support: Dr Durstenfeld is funded by NIH 5K12HL143961. Dr Peluso is funded by NIH K23AI157875. Dr Deeks is funded by NIH UM1AI164560. Dr Hsue is funded by 2K24AI12393-06.

Potential Competing Interests: The authors report no competing interests.

Correspondence: Address to Matthew S. Durstenfeld, MD, Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, SGB, San Francisco, CA 94110. (matthew.durstenfeld@ucsf.edu; Twitter: @durstenfeld).

ORCID
Matthew S. Durstenfeld: https://orcid.org/0000-0002-7612-3352

REFERENCES
1. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. World Health Organization; 2021.
2. Nalbandian A, Sehgal K, Gupta A, et al. Post acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
3. Deer RR, Rock MA, Vasilevsky N, et al. Characterizing long COVID: deep phenotype of a complex condition. EbIoMedicine. 2021;74:103722.
4. Ganesh R, Grach S, Cash A, et al. The female-predominant persistent immune dysregulation of the post-COVID syndrome. Mayo Clinic Proc. 2022;97(3):454-464.
5. Lindahl A, Arro M, Rejula J, et al. Women report more symptoms and impaired quality of life: a survey of Finnish COVID-19 survivors. Infect Dis. (Lond). 2022;54(1):53-62.
6. Seeley J, Waterbeer T, Hippchen T, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. Published online July 5, 2021. https://doi.org/10.1093/cid/ciab611.
7. Blomberg B, Mohr KG, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27(9):1607-1613.
8. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747-758.
9. Kragholm K, Andersen MP, Gerds TA, et al. Association between male sex and outcomes of coronavirus disease 2019 (COVID-19)—a Danish nationwide, register-based study. Clin Infect Dis. 2021;73:e1025-e1030. https://doi.org/10.1093/cid/ciaa929.
10. Forsblom E, Silen S, Kortela E, et al. Male predominance in disease severity and mortality in a low Covid-19 epidemic and low case-fatality area—a population-based registry study. Infect Dis (Lond). 2021;53(10):789-799.
11. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442-447.
12. van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663-673.
13. Goulder P, Deeks SG. HIV control: is getting there the same as staying there? PLoS Pathog. 2018;14(11):e1007222. https://doi.org/10.1371/journal.ppat.1007222.
14. Chertow D, Stein S, Ramelli S, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Preprint. Published online December 20, 2021. In Review. https://doi.org/10.21203/rs.3.rs-1139035/v1.
15. Durstenfeld MS, Peluso MJ, Kelly JD, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in post-acute cardiopulmonary symptoms after SARS-CoV-2 infection. Preprint. Published online November 26, 2021. medRxiv. https://doi.org/10.1101/2021.11.24.21266834.
16. Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839-1848.
17. Patterson BK, Guerra-Coto J, Yogendra R, et al. Immune-based prediction of COVID-19 severity and chronically decoded using machine learning. Front Immunol. 2021;12:700782. https://doi.org/10.3389/ffimm.2021.700782.
18. Ong SWX, Fong SW, Young BE, et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis. 2021;8(6). ofab156. https://doi.org/10.1093/ofid/ofab156.
19. Evans RA, Leavy OC, Richardson M, et al. Clinical characteristics with in-flammation profiling of long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study. Preprint. Posted online December 20, 2021. medRxiv. https://doi.org/10.1101/2021.12.13.21267471.
20. Okamoto LE, Raj SR, Gambao A, et al. Sympathetic activation is associated with increased IL-6, but not CRP in the absence of obesity: lessons from postural tachycardia syndrome and obesity. Am J Physiol Heart Circ Physiol. 2021;320(9):H2098-H2107.
21. Tišler I, Russell IJ, Stewart JM, Gleason RM, Theoharides TC. Neuropeptides CRH SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther. 2016;356(3):664-672.
22. Mendiesta O, De la Cruz-Aguilar DL, Barrera-Villaplano ML, et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol. 2016;290:22-25.
23. Jonjic MA, Olsson GL, Wicksell RK, Alving K, Holmstrom L, Andreasson A. The role of low-grade inflammation in ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome)—associations with symptoms. Psychoneuroendocrinology. 2020;131:05787.
24. Ghosh L, Chamani A, Evrenoglu T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3(3):CD013881. https://doi.org/10.1002/14651858.CD013881.